No prominent role for terminal complement activation in the early myocardial reperfusion phase following cardiac surgery

European Journal of Cardio-thoracic Surgery

Volumn 41, Issue 5, 2012, Pages

  Kortekaas, Kirsten A ^a   van der Pol, Pieter ^a   Lindeman, Jan H N ^a   Baan, Carla C ^b   van Kooten, Cees ^a   Klautz, Robert J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Immunology; Inflammation; Ischaemia; Reperfusion; Surgery

Indexed keywords

COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT C5B 7 COMPLEX; COMPLEMENT C5B-7 COMPLEX; COMPLEMENT COMPONENT C5;

ADULT; AGED; ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEPOSITION; CONTROLLED STUDY; ENDOCARDIUM; HEART FAILURE; HEART GRAFT; HEART MUSCLE; HEART MUSCLE REPERFUSION; HEART SURGERY; HUMAN; HUMAN TISSUE; ISCHEMIC HEART FAILURE; NON ISCHEMIC HEART FAILURE; ORGAN DONOR; PRIORITY JOURNAL; VENOUS BLOOD; CARDIOPULMONARY BYPASS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; REPERFUSION INJURY;

AGED; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; COMPLEMENT C3D; COMPLEMENT C5; HEART FAILURE; HUMANS; MIDDLE AGED; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM;

EID: 84863823731     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezs088     Document Type: Article

References (25)

1. . The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011;108:1133-45
2. Asimakopoulos G. Systemic inflammation and cardiac surgery: an update. Perfusion 2001;16:353-60.
3. Busche MN, Stahl GL. Role of the complement components C5a and C3a in a mouse model of myocardial ischemia and reperfusion injury. Ger Med Sci 2010;8:Doc20.
4. Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001; 104:1413-8:Doc20.
5. Hoel TN, Videm V, Mollnes TE, Saatvedt K, Brosstad F, Fiane AE et al. Off-pump cardiac surgery abolishes complement activation. Perfusion 2007;22:251-6.
6. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304: 497-503.
7. Hoedemaekers C, van Deuren M, Sprong T, Pickkers P, Mollnes TE, Klasen I et al. The complement system is activated in a biphasic pattern after coronary artery bypass grafting. Ann Thorac Surg 2010;89:710-6.
8. Horstick G, Heimann A, Gotze O, Hafner G, Berg O, Bohmer P et al. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997;95:701-8.
9. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-67.
10. Thielmann M, Marggraf G, Neuhauser M, Forkel J, Herold U, Kamler M et al. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg 2006;30:285-93.
11. Fattouch K, Bianco G, Speziale G, Sampognaro R, Lavalle C, Guccione F et al. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg 2007;32: 326-32.
12. Verrier ED, Shernan SK, Taylor KM, Van de Werf F, Newman MF, Chen JC et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 2004;291:2319-27.
13. Hoffmann R, von Bardeleben S, ten Cate F, Borges AC, Kasprzak J, Firschke C et al. Assessment of systolic left ventricular function: a multicentre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J 2005;26:607-16.
14. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
15. Nijmeijer R, Krijnen PA, Assink J, Klaarenbeek MA, Lagrand WK, Veerhuis R et al. C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur J Clin Invest 2004;34: 803-10.
16. Jenkins CP, Cardona DM, Bowers JN, Oliai BR, Allan RW, Normann SJ. The utility of C4d, C9, and troponin T immunohistochemistry in acute myocardial infarction. Arch Pathol Lab Med 2010;134:256-63.
17. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:1008-16.
18. van den Goor J, Nieuwland R, van den Brink A, van Oeveren W, Rutten P, Tijssen J, et al. Reduced complement activation during cardiopulmonary bypass does not affect the postoperative acute phase response. Eur J Cardiothorac Surg 2004;26:926-31.
19. Yasuda M, Takeuchi K, Hiruma M, Iida H, Tahara A, Itagane H et al. The complement system in ischemic heart disease. Circulation 1990;81:156-63.
20. Fitch JC, Rollins S, Matis L, Alford B, Aranki S, Collard CD et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999;100:2499-506.
21. Lazar HL, Bokesch PM, van Lenta F, Fitzgerald C, Emmett C, Marsh HC Jr et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004;110:II274-9.
22. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-8.
23. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM. The role of the complement system in ischemia-reperfusion injury. Shock 2004; 21:401-9.
24. de Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heurn LW, Buurman WA. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004;165:1677-88.
25. Novitzky D, Horak A, Cooper DK, Rose AG. Electrocardiographic and histopathologic changes developing during experimental brain death in the baboon. Transplant Proc 1989;21:2567-9.